News

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.

August was good to U.S. stock investors. All three major U.S. indexes are on track to finish the month in the green—something that has happened since May. The tech-focused Nasdaq is leading the way, up about 4.

August turned out to be a pretty good month for S&P 500 investors. And some stocks wound up having a great month.

For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. The pharma industry is entering its biggest wave of patent expirations in decades. The world’s bestselling drug in 2025, Merck’s cancer immunotherapy Keytruda, loses U.S. patent protection in 2028, and nearly every pharma company has at least one blockbuster drug that will go off patent in the next five years.

Over the past 12 months, the State Street SPDR S&P Biotech ETF is up around 85% versus roughly 20% for the S&P 500. Last week added an exclamation point: Moderna more than doubled in a single session after its mRNA cancer vaccine, developed with Merck, cleared a late-stage melanoma trial. For decades, U.S. and other Western companies enjoyed something close to a monopoly on cutting-edge science.

All three major US stock indexes were up in late-morning trading Thursday, after Nvidia (NVDA) relea

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6%, and the actively tra

Stock futures were pointing lower ahead of what’s likely to be a big day for the tech sector and the broader market.

Gain insight on Moderna, Novo Nordisk and more in the latest Market Talks covering the Health Care sector.

Merck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle.

Nvidia (NVDA) is just days away from releasing second quarter earnings results this Wednesday, August 26, as Wall Street expects quarterly revenue of $92 billion. The Morning Brief's Jake Conley sits down with Barron's senior markets analysis writer Paul La Monica and Infrastructure Capital Advisors CEO Jay Hatfield to discuss why excellent earnings may still not be enough to impress investors in this stage of the AI cycle.

Stock futures are falling to start the week with tech names leading the way lower ahead of Nvidia’s key earnings report.

Moderna has always been a stock driven by narrative extremes. During the pandemic, it traded as if mRNA would transform medicine overnight, with its market capitalization peaking near $200 billion. Shares exploded 177% in a single session on Wednesday—the largest one-day surge for an S&P 500 company in over two decades—after Moderna and partner Merck reported successful late-stage trial results for their personalized mRNA melanoma vaccine.

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.

Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marvel."

The stock market still looks basically healthy, but the bond market is starting to show signs of stress.

Investing.com -- A historic single-day move in biotech dominated the week, while a Treasury liquidity announcement impacted crypto and metals. Two well-known consumer names went in opposite directions on earnings.

The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped. Walmart dived.

After ripping through the first half of the year, memory stocks are struggling to regain momentum as growing concerns about the state of the artificial intelligence trade overshadow their strong fundamental backdrop.

Find insight on Moderna, Merck KGaA, Novonesis and more in the latest Market Talks covering the health care sector.

The day after Moderna’s stock posted its biggest one-day gain on record, it is on track for its largest percent drop in more than two years as investors digested the news and adjusted their positions. Prior to Wednesday’s rally on positive mRNA cancer vaccine data, Moderna’s stock had substantial short interest at 13.7%. UBS said its clients sold a record $44 million in Moderna shares Wednesday, suggesting some investors were cashing out after the rally.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.

Dow Jones futures: Crude oil continues to climb while bitcoin jumped again amid a weak dollar. Walmart earnings are in focus.

By Mike Dolan Aug 20 (Reuters) - What matters in U.S. and global markets today By Mike Dolan, Editor-at-Large, Finance and Markets Buybacks to the rescue? The surprising move by the U.S.

Promising news from a major drug company, reports of some dovish Fed committee members, and a government bond buyback announcement combined forces to boost markets on Wednesday. The S&P 500 and the Nasdaq Composite also closed up 0.2%. The Treasury Department’s announcement this morning also helped calm the bond market—though for how long remains to be seen after the U.S. debt crossed a $40 trillion threshold on Wednesday.

<body><p>VIDEO SHOWS: n/a</p><p>STORY: Wall Street's main indexes closed modestly higher on Wednesday, with the Dow, S&P 500 and the Nasdaq all adding less than a quarter of a percent.</p><p>Risk appetite got a boost from easing government bond yields. The yield on the 30-year Treasury bond fell a day after hitting its highest level since 2007. The 10-year Treasury yield also fell. The moves came after the U.S. Treasury announced it would double the size of liquidity support buyback operations for longer-dated bonds.</p><p>Adam Coons is chief investment officer at Winthrop Capital Management.</p><p>"Stocks are, you know, marginally up today. And that's really just driven by the digestion of this yield curve control. You're seeing interest rates come down, in particular long end (long-term rates) quite a bit. And so you're probably going to see markets try to use their crystal ball to determine what's coming next. And so I would expect volatility. Today seems like a day of rest to some degree. But I would say that volatility and increased volatility heading into, you know, changes in Fed policy should be the new expectation."</p><p>Investors, however, barely reacted to minutes from the Federal Reserve's July meeting, which showed deepening concern about inflation with "several" policymakers ready to raise interest rates. "Many" said a rate hike would be needed if inflation does not lower to the central bank's 2% target.</p><p>:: Archive</p><p>Stocks on the move Wednesday included Moderna which surged almost 177% after the company said its personalized mRNA cancer therapy developed with Merck cut the risk of melanoma recurrence and spread in a late-stage trial. Merck shares also jumped about 12.5% and it was the biggest gainer in the Dow.</p><p>::Marvell Technology</p><p>Shares of Marvell Technology climbed nearly 10% after the company said it will help develop Google's in-demand custom chips and has offered the search giant the right to buy a potential $12.2 billion stake.</p><p>And shares of Target rose more than 4% after the retailer raised its annual sales forecast. Lowe's shares gained even after it trimmed its annual sales growth forecast and Estée Lauder shares jumped more than 16% after the cosmetics maker forecast annual profit above Wall Street estimates.</p></body>

(Updates with market moves at the end of the day, and other changes, if any.) Wall Street's main

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late-stage trial at preventing melanoma from returning or spreading. The S&P health-care sector is on track for an all-time closing high, as is Merck, according to data that goes back to 1972. As of Wednesday afternoon, Moderna’s stock had more than doubled, something that a member of the S&P 500 hasn't done in a single day since 2008, according to Dow Jones Market Data.